THE VALUE OF ALPHA FETOPROTEIN COMBINED WITH ABNORMAL PROTHROMBIN IN THE DIAGNOSIS OF PRIMARY LIVER CANCER

Haixia Liu¹, Fengyun Chen^{2, *}

¹Department of Gastroenterology, Baoji Central Hospital, Baoji 721008, PR China - ²Department of Hematology and Rheumatology, Baoji Central Hospital, Baoji 721008, PR China

Objective: The aim of the study was to explore the value of alpha fetoprotein combined with abnormal prothrombin in the diagnosis of primary liver cancer. 

Methods: From January 2017 to January 2019, 80 patients with primary liver cancer were selected as the study group. An additional 80 patients with digestive system diseases, but without primary liver cancer were selected as the benign control group, and 80 normal patients were selected as the normal control group. The abnormal prothrombin in serum was detected using enzyme-linked immunosorbent assay (ELISA), and the AFP level was detected using electrochemiluminescence. Following the treatment, the serum AFP and abnormal prothrombin were detected. 

Result: The levels of serum AFP and abnormal prothrombin in the study group were significantly higher than those in the benign control group and the normal control group, and there was a statistical difference between the two groups (p<.05). Following the systematic treatment of patients with primary liver cancer, it was found that the levels of serum AFP and abnormal enzymes in these patients were significantly lower than those before treatment (p<.05). 

Conclusion: Alpha fetoprotein and abnormal prothrombin have specific diagnostic value for primary liver cancer and can better reflect the clinical therapeutic effects of primary liver cancer patients.